Institution · Entasis Therapeutics (United States)

Most cited papers from Entasis Therapeutics (United States)

Entasis Therapeutics (United States)

What are the most cited papers from Entasis Therapeutics (United States)?

The most cited paper from Entasis Therapeutics (United States) is "ESKAPEing the labyrinth of antibacterial discovery" (Rubén Tommasi, Dean G. Brown, Grant K. Walkup et al., 2015), with 628 citations. Next come "Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial" (328) and "Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)" (316).

Published TypeFieldAccessCitations

Showing 50 of 99 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	ESKAPEing the labyrinth of antibacterial discovery Rubén Tommasi, Dean G. Brown, Grant K. Walkup et al. · Nature Reviews Drug Discovery Review	3 Jul 2015	628
2	Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial Elizabeth Berry‐Kravis, David R. Hessl, Barbara Rathmell et al. · Science Translational Medicine Open access	19 Sep 2012	328
3	Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink et al. · The Lancet Infectious Diseases	11 May 2023	316
4	ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii Thomas F. Durand-Réville et al. · Nature Microbiology	29 Jun 2017	283
5	Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABA B Receptors with Arbaclofen Christina Henderson, Lasani S. Wijetunge, Mika Kinoshita et al. · Science Translational Medicine Open access	19 Sep 2012	251
6	Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea Stephanie N. Taylor, Jeanne Marisa Marrazzo, Byron E. Batteiger et al. · New England Journal of Medicine Open access	7 Nov 2018	249
7	Isolation of a Family of Organic Anion Transporters from Human Liver and Kidney William Y. Sun, Rong Wu, Paul D. van Poelje et al. · Biochemical and Biophysical Research Communications	May 2001	218
8	Dosing With 5% Imiquimod Cream 3 Times per Week for the Treatment of Actinic Keratosis Neil J. Korman, Ron Moy, MARK R. LING et al. · Archives of Dermatology	Apr 2005	165
9	Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae , Including Multi-Drug-Resistant Isolates Patricia A. Bradford, Alita A. Miller, John P. O’Donnell et al. · ACS Infectious Diseases Open access	24 Apr 2020	157
10	Rational design of a new antibiotic class for drug-resistant infections Thomas F. Durand-Réville et al. · Nature	15 Sep 2021	142
11	Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent Melissa D. Barnes, Vijay Kumar, Christopher R. Bethel et al. · mBio Open access	11 Mar 2019	120
12	In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii - calcoaceticus Complex Collected from 2016 to 2021 James A. Karlowsky, Meredith Hackel, Sarah M. McLeod et al. · Antimicrobial Agents and Chemotherapy Open access	25 Aug 2022	112
13	Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases Gregory S. Basarab et al. · Scientific Reports Open access	14 Jul 2015	109
14	Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin Ramkumar Iyer, Samir H. Moussa, Thomas F. Durand-Réville et al. · ACS Infectious Diseases	20 Dec 2017	95
15	In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii- calcoaceticus Complex Isolates Collected Globally in 2016 and 2017 Sarah M. McLeod, Samir H. Moussa, Meredith Hackel et al. · Antimicrobial Agents and Chemotherapy Open access	24 Jan 2020	94
16	Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam Adam B. Shapiro, Samir H. Moussa, Sarah M. McLeod et al. · Frontiers in Microbiology Open access	19 Jul 2021	88
17	In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii Harald Seifert, Carina Müller, Danuta Stefanik et al. · Journal of Antimicrobial Chemotherapy	May 2020	80
18	Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam Adam B. Shapiro · Antimicrobial Agents and Chemotherapy Open access	3 Oct 2017	72
19	Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects Keith A. Rodvold, Mark H. Gotfried, Robin Isaacs et al. · Antimicrobial Agents and Chemotherapy Open access	17 Aug 2018	69
20	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases Thomas F. Durand-Réville, Janelle Comita-Prevoir, Jing Zhang et al. · Journal of Medicinal Chemistry Open access	13 Jul 2020	63
21	Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii Sarah M. McLeod, Adam B. Shapiro, Samir H. Moussa et al. · Antimicrobial Agents and Chemotherapy Open access	13 Nov 2017	63
22	Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514 Adam B. Shapiro, Ning Gao, Haris Jahić et al. · ACS Infectious Diseases	24 Aug 2017	63
23	Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis Olexiy Sagan, Ruslan Yakubsevitch, Krassimir Prodanov Yanev et al. · Antimicrobial Agents and Chemotherapy Open access	16 Dec 2019	58
24	Antibacterial Drug Discovery: Some Assembly Required Rubén Tommasi, Ramkumar Iyer, Alita A. Miller · ACS Infectious Diseases	27 Feb 2018	58
25	Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species Krisztina M. Papp‐Wallace, Sarah M. McLeod, Alita A. Miller · Clinical Infectious Diseases Open access	16 Feb 2023	56
26	Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii Samir H. Moussa, Adam B. Shapiro, Sarah M. McLeod et al. · Antimicrobial Agents and Chemotherapy Open access	16 Oct 2023	51
27	Agonists and Antagonists of Protease-Activated Receptor 2 Discovered within a DNA-Encoded Chemical Library Using Mutational Stabilization of the Target Dean G. Brown et al. · SLAS DISCOVERY Open access	12 Jan 2018	48
28	Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action Khalid M Dousa, David C. Nguyen, Sebastian G. Kurz et al. · mBio Open access	25 Jan 2022	46
29	Whole-Cell-Based Assay To Evaluate Structure Permeation Relationships for Carbapenem Passage through the Pseudomonas aeruginosa Porin OprD Ramkumar Iyer, Mark A. Sylvester, Camilo Velez‐Vega et al. · ACS Infectious Diseases	3 Feb 2017	45
30	Thyroid hormone β receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys BR Ito, B. L. Zhang, Edward E. Cable et al. · British Journal of Pharmacology Open access	22 Jan 2009	44
31	Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii Sarah M. McLeod, John P. O’Donnell, Navaneeth Narayanan et al. · Future Microbiology Open access	Mar 2024	41
32	Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects John P. O’Donnell, Richard Arthur Preston, Grigor Mamikonyan et al. · Antimicrobial Agents and Chemotherapy Open access	10 Jul 2019	39
33	Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914) Xiaohong Su, Baoxi Wang, Wenjing Le et al. · Antimicrobial Agents and Chemotherapy Open access	20 Oct 2015	34
34	The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex John P. O’Donnell, Sujata M. Bhavnani · Clinical Infectious Diseases Open access	May 2023	33
35	In Vitro Characterization of ETX1317, a Broad-Spectrum β-Lactamase Inhibitor That Restores and Enhances β-Lactam Activity against Multi-Drug-Resistant Enterobacteriales , Including Carbapenem-Resistant Strains Alita A. Miller, Adam B. Shapiro, Sarah M. McLeod et al. · ACS Infectious Diseases Open access	7 Apr 2020	33
36	Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers John P. O’Donnell, K. W. Lawrence, Karthick Vishwanathan et al. · Antimicrobial Agents and Chemotherapy Open access	30 Oct 2018	32
37	Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics David Altarac, Michael Gutch, John P. Mueller et al. · Drug Discovery Today Open access	21 Feb 2021	30
38	Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Neisseria gonorrhoeae Clinical Isolates in Nanjing, China, 2014 to 2018 Wenjing Le, Xiaohong Su, Xiangdi Lou et al. · Antimicrobial Agents and Chemotherapy Open access	15 Dec 2020	30
39	I n vitro pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex John P. O’Donnell, Angela Tanudra, April Chen et al. · Antimicrobial Agents and Chemotherapy Open access	11 Dec 2023	27
40	Ceftazidime–Avibactam Resistance Mutations V240G, D179Y, and D179Y/T243M in KPC-3 β-Lactamase Do Not Alter Cefpodoxime–ETX1317 Susceptibility Adam B. Shapiro, Samir H. Moussa, Nicole Carter et al. · ACS Infectious Diseases Open access	9 Dec 2020	27
41	Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects Jason D. Lickliter, Kenneth R Lawrence, John P. O’Donnell et al. · Antimicrobial Agents and Chemotherapy Open access	9 Apr 2020	27
42	Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones Gregory S. Basarab, Sandeep R. Ghorpade, Liezl Gibhard et al. · Antimicrobial Agents and Chemotherapy Open access	10 Mar 2022	26
43	In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione John R. Papp, Kenneth R Lawrence, Samera Sharpe et al. · International Journal of Antimicrobial Agents Open access	15 Jul 2016	26
44	Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection—Clinical Trial Group Programmatic Meeting Anthony D. Cristillo, Claire Bristow, Elizabeth Torrone et al. · Sexually Transmitted Diseases Open access	24 Oct 2018	24
45	Update on Treatment Options for Gonococcal Infections Jason W. Lancaster, Monica V. Golik Mahoney, Sana Mandal et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	Sep 2015	22
46	N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay Takeru Furuya, Adam B. Shapiro, Janelle Comita-Prevoir et al. · Bioorganic & Medicinal Chemistry Open access	27 Oct 2020	21
47	Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea—challenges and opportunities Ursula Theuretzbacher, Lindley A. Barbee, Kristie L. Connolly et al. · Clinical Microbiology and Infection Open access	13 Aug 2020	21
48	Oxazole phosphonic acids as fructose 1,6-bisphosphatase inhibitors with potent glucose-lowering activity Qun Dang, Srinivas Rao Kasibthatla, Tao Jiang et al. · MedChemComm	2011	19
49	Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK) Alita A. Miller, Samir H. Moussa, Sarah M. McLeod · Antimicrobial Agents and Chemotherapy Open access	3 Apr 2024	18
50	Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282 John P. O’Donnell, Angela Tanudra, April Chen et al. · ACS Infectious Diseases Open access	7 May 2020	18

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.